Chemicon International, a division of Norcross-based Serologicals Corp., has entered into an exclusive agreement with the development arm of Ireland-based ThromboGenics Ltd. to market an embryonic stem cell culture medium of great benefit to drug development research, according to a recent Serologicals announcement.
Serologicals Corp. is a global provider of biological products and enabling technologies to life science companies.
The cell culture medium is expected to be widely used in the drug discovery arena due to its superiority over conventional stem cell culture systems and its ability to be used with a broad range of stem cell lines derived from mouse strains, according to the statement.
Mouse strains are widely used in drug development research.
Chemicon will offer these products through its sales teams in Australia, much of Europe, North America and the United Kingdom.
For more information, contact Bill Davis, Serologicals’ public affairs manager, at (678) 728-2018.